Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome

Breast Cancer Research and Treatment
Jacques Raphael, S Verma

Abstract

Overall survival (OS) has been debated as the most important clinical endpoint in metastatic breast cancer (MBC) trials mainly because survival could be influenced by treatment after progression in an era of effective subsequent-line agents. We conducted a search strategy using PubMed for all the phase 3 trials in the last two decades evaluating survival outcome in MBC. We investigated the frequency of trials reporting survival outcome and response/resistance to treatment beyond progression. One hundred fifteen trials met our eligibility criteria: 69 (60 %) evaluated chemotherapy regimens (group A), 32 (28 %) evaluated targeted therapies (group B), and 14 (12 %) focused on endocrine treatment (group C). An OS benefit was demonstrated in approximately 22 % of the trials in each group. Less than 10 % of the trials in group A and B reported response data after progression on trial therapy. Post-progression treatment resistance was only reported in group A in 3 % (2/69) of the trials. In addition, the number of lines of treatment used post-progression was reported in 14 % (10/69), 9.4 % (3/32), and 14 % (2/14) of the trials in group A, B, and C, respectively. Post-progression survival and its effect on OS was reported in only 1 % (...Continue Reading

References

Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoM J Piccart
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice AndreMarc Spielmann
Feb 14, 2006·Seminars in Oncology·Ian Smith
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz BurzykowskiPatrick Therasse
Jul 25, 2008·Clinical Breast Cancer·Stephen E Jones
Aug 30, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicholas Wilcken, Rachel Dear
Oct 3, 2008·International Journal of Technology Assessment in Health Care·Rebecca A MiksadUwe Siebert
Nov 22, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Windy Dean-Colomb, Francisco J Esteva
Dec 11, 2008·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Dec 20, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E D Saad, A Katz
Nov 12, 2009·Journal of the National Cancer Institute·Kristine R Broglio, Donald A Berry
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everardo D SaadMarc Buyse
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A SparanoPierfranco Conte
Oct 23, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Roché, L T Vahdat
Dec 2, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C A HarrisS Pearson
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward L KornJeffrey S Abrams
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stephen R D Johnston
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Dec 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiang H-F ZhangC Kent Osborne
Aug 3, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I F Tannock, G R Pond
Sep 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PiccartJ Baselga
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter A KaufmanJavier Cortes
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group
Feb 1, 2006·Seminars in Oncology·Ian Smith

❮ Previous
Next ❯

Citations

Sep 3, 2016·Journal of Cancer Research and Clinical Oncology·Seung Yeon SongEun Young Kim
Oct 30, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E VrdoljakG von Minckwitz
Mar 7, 2019·JCO Clinical Cancer Informatics·Gabrielle B RocqueKelly M Kenzik
Apr 1, 2020·American Society of Clinical Oncology Educational Book·Andrew D SeidmanJulia A Beaver
Jan 29, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Chenhao WuChen Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.